Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from NovoCure ( (NVCR) ) is now available.
Novocure’s Phase 3 PANOVA-3 trial has shown promising results in treating unresectable, locally advanced pancreatic cancer with Tumor Treating Fields (TTFields) therapy, improving median overall survival by 2 months compared to standard treatment. The study, which is paving the way for regulatory approval in major markets, highlights TTFields as a well-tolerated and effective first-line therapy option, offering hope for better outcomes in a notoriously challenging cancer type.
See more insights into NVCR stock on TipRanks’ Stock Analysis page.
